Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Haemonetics (HAE) Shares Issued (2016 - 2025)

Haemonetics has reported Shares Issued over the past 17 years, most recently at $1.1 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 127.13% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $2.2 million, up 19.48%, while the annual FY2024 figure was $1.6 million, 38.97% down from the prior year.
  • Shares Issued for Q4 2025 was $1.1 million at Haemonetics, up from $63000.0 in the prior quarter.
  • Over five years, Shares Issued peaked at $2.4 million in Q2 2021 and troughed at $63000.0 in Q3 2025.
  • A 5-year average of $650210.5 and a median of $462000.0 in 2025 define the central range for Shares Issued.
  • Biggest five-year swings in Shares Issued: soared 1519.7% in 2021 and later crashed 86.27% in 2022.
  • Year by year, Shares Issued stood at $1.1 million in 2021, then plummeted by 85.03% to $160000.0 in 2022, then increased by 16.25% to $186000.0 in 2023, then soared by 171.51% to $505000.0 in 2024, then surged by 127.13% to $1.1 million in 2025.
  • Business Quant data shows Shares Issued for HAE at $1.1 million in Q4 2025, $63000.0 in Q3 2025, and $462000.0 in Q2 2025.